siRNAs articles within Nature Reviews Cardiology

Featured

• Research Highlight | 06 November 2023

  Patisiran is beneficial for the treatment of TTR cardiac amyloidosis

  Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.

  • Irene Fernández-Ruiz

• Research Highlight | 31 July 2023

  Promising novel siRNA for the treatment of hypertension

  Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study.

  • Irene Fernández-Ruiz

• Research Highlight | 16 November 2022

  siRNA therapy markedly reduces Lp(a) levels

  Olpasiran, a small interfering RNA (siRNA) that reduces lipoprotein(a) (Lp(a)) production in the liver, administered every 12 weeks induces a pronounced and sustained decrease in the plasma levels of Lp(a) in patients with established atherosclerotic cardiovascular disease, according to findings from the OCEAN(a)-DOSE trial.

  • Irene Fernández-Ruiz